Table 1.
Characteristics of HIV-infected individuals and healthy donors.
| PID | Age | Gender | Ethnicity | Duration of HIV infection, years |
Duration of viral suppression* |
ART regimen | Plasma HIV RNA (copies/mL) |
Stage of infection |
CD4+ count (cells/μL) |
Elite controllers |
|---|---|---|---|---|---|---|---|---|---|---|
| 529 | 59 | Male | Non-Hispanic | 0.3 | Intermittent suppression | GENVOYA | 585,100 | Chronic | 203 | No |
| 717 | 56 | Male | African American | 27 | Intermittent suppression | DESCOVY + TRUVADA + PREZISTA + PREZCOBIX + NORVIR |
185,072 | Chronic | 299 | No |
| 168 |
36 |
Male |
African American |
3.5 |
Never suppressed |
– |
259,111 |
Chronic |
37 |
No |
| 876 | 33 | Male | White | 7.6 | Fully suppressed | Triumeq | <20 | Chronic | 806 | No |
| 630 | 58 | Male | other race | 22 | Fully suppressed | ODEFSEY + TIVICAY | <20 | Chronic | 603 | No |
| 471 |
60 |
Male |
other race |
11 |
Fully suppressed |
JULUCA |
<20 |
Chronic |
638 |
No |
| HD1 | 22 | Female | Non-Hispanic | – | – | – | – | – | – | |
| HD2 | 23 | Male | White | – | – | – | – | – | – | |
| HD3 | 50–60 | Male | other race | – | – | – | – | – | – | |
| HD4 | 70–75 | Male | other race | – | – | – | – | – | – |
* Duration of viral suppression: fully suppressed (plasma HIV viral load < 50 copies/mL for >6 months), never suppressed (No ART treatment), intermittent suppression (ART treatment and plasma HIV viral load >50 copies/mL)